Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities from Discontinued Operations (2016 - 2018)

Soleno Therapeutics (SLNO) has disclosed Liabilities from Discontinued Operations for 3 consecutive years, with 110000.0 as the latest value for Q3 2018.

  • For Q3 2018, Liabilities from Discontinued Operations changed N/A year-over-year to 110000.0; the TTM value through Sep 2018 reached 110000.0, changed N/A, while the annual FY2017 figure was 225000.0, 177.78% up from the prior year.
  • Liabilities from Discontinued Operations hit 110000.0 in Q3 2018 for Soleno Therapeutics, down from 1050000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 1050000.0 in Q2 2018 and bottomed at 81000.0 in Q4 2016.
  • Average Liabilities from Discontinued Operations over 3 years is 310800.0, with a median of 110000.0 recorded in 2018.
  • On a YoY basis, Liabilities from Discontinued Operations climbed as much as 177.78% in 2017 and fell as far as 177.78% in 2017.
  • Soleno Therapeutics' Liabilities from Discontinued Operations stood at 81000.0 in 2016, then soared by 177.78% to 225000.0 in 2017, then crashed by 51.11% to 110000.0 in 2018.
  • According to Business Quant data, Liabilities from Discontinued Operations over the past three periods came in at 110000.0, 1050000.0, and 88000.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.